Lund

• A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for … Ended recruitment
  2024-517321-99-00 4 2016-08-01 Myeloma multiplex
• CheckMate 274 Ended recruitment
  2022-500630-29-00 5 2016-05-06 Subjects with High Risk Invasive Urothelial Carcinoma
• An open label, multi-center, Phase IV rollover protocol to evaluate long term safety data Ended recruitment
  2024-515283-31-00 6 2015-07-30 This study is designed to accept patients with varied disease origins,
• A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi … Ended recruitment
  2023-509348-84-00 5 2015-04-27 Chronic Lymphocytic Leukemia
• PREDIX HER2 - preoperative treatment of HER2 positive breast cancer Ended recruitment
  2023-508411-23-00 4 2014-11-12 Primary breast cancer
• Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit … Ended recruitment
  2024-512243-23-00 5 2014-11-07 gastrointestinal stromal tumor
• A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke Halted
  2023-506178-11-00 5 2025-11-11 Acute ischemic stroke
• Safety Trial, DSC vs. BAT in SR acute GvHD Ended
  2024-511768-97-01 4 2024-11-20 Graft vs Host Disease
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended
  2024-511557-21-00 5 2024-11-14 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A multi-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of all … Ended
  2024-518757-42-00 9 2024-10-28 Difficult-to-heal venous leg ulcers
• Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dos … Ended
  2023-506000-50-00 4 2024-09-26 Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-H
• A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis Ended
  2023-510249-79-00 4 2024-09-10 Progressive pulmonary fibrosis (PPF)
• A Phase 3, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adu … Ended
  2023-507268-37-00 5 2024-07-29 Hereditary Angioedema
• Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction Ended
  2023-506210-40-00 5 2024-06-28 Heart Failure due to Systemic Left Ventricular Systolic Dysfunction
• A study to learn how safe starting vericiguat at a dose of 5 milligrams is in participants with chronic heart failure with reduced ejection … Ended
  2023-507682-25-00 4 2024-05-13 Chronic heart failure with reduced ejection fraction
• Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to … Ended
  2022-503066-74-00 7 2023-12-04 Advanced solid tumors
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight … Ended
  2022-502678-18-00 5 2023-11-07 Type 2 diabetes
• A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o … Ended
  2023-509833-38-00 5 2023-09-20 Birch Pollen-induced Allergic Rhinoconjunctivitis
• A Clinical Study that will measure how well SEP-363856 works and how safe it is in adults with Generalized Anxiety Disorder Ended
  2022-502077-42-00 10 2023-09-14 generalised anxiety disorder
• A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary … Ended
  2022-500746-16-00 4 2023-08-11 Geographic Atrophy
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE study) Ended
  2022-501783-18-00 4 2023-07-21 Parkinson’s Disease
• A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended
  2023-508163-74-00 5 2023-06-12 Major Depressive Disorder
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th … Ended
  2022-500121-33-01 5 2023-05-08 Anti-GBM antibody disease (Goodpasture disease)
• KANDOVA An open multicenter study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determ … Ended
  2024-515572-13-00 9 2023-04-26 Recurrent epithelial ovarian, fallopian tube, or primary peritoneal ca

Showing 241–264 of 308 trials